PARI Pharma GmbH, Aerosol Research Institute, Lochhamer Schlag 21, D-82166 Graefelfing, Germany.
Expert Opin Drug Deliv. 2011 Jan;8(1):1-17. doi: 10.1517/17425247.2010.542141.
Disodium cromoglycate (DSCG) fits with the perception of a safe drug, but conclusions from questionable meta-analyses reduced its use. In addition, drug delivery aspects, such as hygroscopicity and the poor performance of delivery systems, were not considered to be important determinants of therapeutic failures.
Drug delivery aspects and parameters affecting lung deposition and distribution, important parameters for therapeutic efficacy, are addressed. In addition, the distribution and ratio of mast cell tryptase and chymase-positive phenotypes in the lungs and their role in the prostaglandin and leukotriene pathway are discussed.
Information on why in vitro data are an excellent tool to understand better therapeutic failures associated with the moisture sensitivity of DSCG and the difficulty in handling and operating DSCG delivery systems in a therapeutically reliable way.
Pharmacological efficacy of DSCG has been demonstrated in animals and humans. If the drug is delivered to the site of inflammation in an effective dose, a reliable therapeutic effect can be expected. DSCG has extra properties and potential unspecific antiviral properties and may offer new therapeutic treatment aspects for asthma and viral-induced bronchiolitis in early childhood.
二钠色甘酸（DSCG）符合安全药物的认知，但有问题的荟萃分析的结论减少了其使用。此外，药物输送方面，如吸湿性和输送系统性能不佳，并未被认为是治疗失败的重要决定因素。
涉及药物输送方面和影响肺部沉积和分布的参数，这些都是治疗效果的重要参数。此外，还讨论了肺部肥大细胞胰蛋白酶和糜蛋白酶阳性表型的分布和比例及其在前列腺素和白三烯途径中的作用。
了解为什么体外数据是理解与 DSCG 的湿度敏感性相关的治疗失败以及以治疗可靠的方式处理和操作 DSCG 输送系统的困难的重要工具。
DSCG 的药理疗效已在动物和人类中得到证实。如果将药物以有效剂量递送到炎症部位，则可以预期可靠的治疗效果。DSCG 具有额外的特性和潜在的非特异性抗病毒特性，可能为哮喘和幼儿期病毒引起的细支气管炎提供新的治疗方法。
